Jörg Möhrle
Leadership in malaria-focused translational development.
Kinga Bora AG is developing a new generation of malaria vaccines designed to reduce severe disease burden where malaria becomes life-threatening, especially for children.
That malaria is not only fatal: it can remove years of education, income, and opportunity. A sick child affects the entire household, with downstream effects on human capital and long-term development.
School days missed per episode
Caregiver workdays lost
Potential annual household income loss
Higher risk of lasting cognitive impairment after severe malaria
Rising temperatures, flooding, and shifting mosquito habitats are factors that could broaden transmission zones beyond traditionally high-burden regions.
A vaccine concept designed to block parasite multiplication in the bloodstream, creating a longer time window to act than first-generation approaches that target the earliest stage of liver invasion.
Early-stage vaccines try to block the parasite before liver invasion.
Kinga Bora focuses on preventing multiplication during the bloodstream phase.
A longer intervention window may help reduce severe disease impact.
The target is presented as a potential weak point of the parasite.
Manufacturing work, prototype development, rabbit immunogenicity testing, and early regulatory preparation.
GxP material manufacturing and GLP toxicology activities to support further advancement.
Initial human studies planned in Australia, according to the roadmap in the presentation.
Blood-stage challenge study planned in Australia.
African challenge study and pediatric Phase 2b progression form key value inflection points.
A late-stage strategy built around donor alignment, non-dilutive funding, and partnership with a multinational pharmaceutical company for approval, mass manufacturing, and distribution.
Enabling IP has been secured and additional patent filing activity is ongoing.
Deep expertise spanning malaria, vaccines, global health, mRNA technologies, biotech company building, finance, and translational development.
Leadership in malaria-focused translational development.
Scientific leadership with malaria immunology and Swiss TPH research background.
Biotech company-building, governance, investor relations, and fundraising support.
mRNA platform, RNA technologies, and scale-up.
Global-health, epidemiology, and malaria field expertise.
CFO, accounting, controlling, administration, translation, and laboratory roles support execution.